EUVIMEDEUVIMED entdecken
Leitlinie

How to monitor and manage unfractionated heparin in practice (Part 1)? Guidance from the SSC of the ISTH

Isabelle Gouin-Thibault, Corinne Frere, Lana A Castellucci, Jean M Connors, Adam Cuker, Jerrold H Levy, Thomas Lecompte, Francois Mullier, UFH working group

Journal of Thrombosis and Haemostasis · 2026-08 · 24 (8) · 3051-3062

DOI: 10.1016/j.jtha.2026.05.013 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-08. Verfasst von Isabelle Gouin-Thibault und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Hematology, Pontchaillou University Hospital of Rennes, University of Rennes, IRSET-INSERM-1085, INNOVTE network, Rennes, Fr…. Hauptthemen laut MEDLINE: Anticoagulants, Blood Coagulation, Drug Monitoring, Heparin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 75 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The International Society on Thrombosis and Haemostasis (ISTH) recently published a survey on the management of unfractionated heparin (UFH), which revealed substantial heterogeneity in practice and highlighted the need to develop evidence-based guidance. This document summarizes evidence and provides consensus guidance, developed through a Delphi process, for preanalytical, analytical, and clinical aspects of UFH management. For preanalytical issues, optimal practice includes centrifuging blood samples within 1 hour of collection and testing within 10 minutes of centrifugation, although a 1-hour interval is acceptable. Standard 3.2% (109 mM) buffered trisodium citrate tubes are recommended, with no routine use of CTAD (citrate, theophylline, adenosine, and dipyridamole) tubes due to cost and uncertain benefit. Analytically, anti-Xa assays are preferred over activated partial thromboplastin time for UFH monitoring, as they are less affected by interferences and do not require the determination of a local range. Assays without dextran sulphate or added antithrombin are optimal, especially to avoid overestimating UFH activity after protamine reversal. Establishing a local heparin therapeutic range is essential if activated partial thromboplastin time is used. Clinically, a target anti-Xa level of 0.30 to 0.70 U/mL is suggested for most indications, including venous thromboembolism, arterial events, and mechanical heart valves. Weight-based nomograms are recommended for dosing, although no single nomogram is preferred due to limited outcome data. Antithrombin supplementation is generally not advised for acquired deficiency. The guidance highlights critical evidence gaps and calls for further research to optimize UFH monitoring and dosing, with future documents addressing special populations and periprocedural management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsBlood CoagulationDrug MonitoringHeparinHumansBlood Coagulation TestsConsensusFactor Xa InhibitorsPartial Thromboplastin TimePredictive Value of Tests

Stichwörter der Autor:innen

anti-Xaantithrombinarterial thromboembolismmonitoringvenous thromboembolism

Substanzen

AnticoagulantsFactor Xa InhibitorsHeparin

Autor:innen und Institutionen

  • Department of Laboratory Hematology, Pontchaillou University Hospital of Rennes, University of Rennes, IRSET-INSERM-1085, INNOVTE network, Rennes, France. Electronic address: isabelle.gouin@chu-rennes.fr.
  • Department of Hematology, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, INSERM UMR_S 1166, INNOVTE network, Paris, France.
  • Department of Medicine, University of Ottawa and the Ottawa Hospital Research Institute, Ontario, Canada.
  • Cancer Hematology Division, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Medicine and Department of Pathology & Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Anesthesiology, Critical Care and Surgery, Duke University School of Medicine, Durham, North Carolina, USA.

Zitieren

APA

Gouin-Thibault, I., Frere, C., Castellucci, L. A., Connors, J. M., Cuker, A., Levy, J. H., Lecompte, T., Mullier, F., & UFH working group (2026). How to monitor and manage unfractionated heparin in practice (Part 1)? Guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 24(8), 3051-3062. https://doi.org/10.1016/j.jtha.2026.05.013

Vancouver

Gouin-Thibault I, Frere C, Castellucci LA, Connors JM, Cuker A, Levy JH, et al. How to monitor and manage unfractionated heparin in practice (Part 1)? Guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 2026;24(8):3051-3062. doi:10.1016/j.jtha.2026.05.013

BibTeX
@article{GouinThibault2026,
  author = {Gouin-Thibault, Isabelle and Frere, Corinne and Castellucci, Lana A and Connors, Jean M and Cuker, Adam and Levy, Jerrold H and Lecompte, Thomas and Mullier, Francois and UFH working group, UFH working group},
  title = {How to monitor and manage unfractionated heparin in practice (Part 1)? Guidance from the SSC of the ISTH},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2026},
  volume = {24},
  number = {8},
  pages = {3051--3062},
  doi = {10.1016/j.jtha.2026.05.013}
}
Kostenlos starten →